SUBSCRIBE
SUBSCRIBE
News   Business

Dyax Corp. Posts Wider Q1 Loss, Says Has Enough Cash Till 2010

April 22, 2009 | 
1 min read

Reuters -- Biotechnology company Dyax Corp (DYAX.O) posted a wider first-quarter loss on higher research and development expense, and job-cut related charges, but said it has enough cash to continue operations into 2010.

Earnings
MORE ON THIS TOPIC
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Eli Lilly's biotechnology center in California
Manufacturing
Lilly Pumps $3B Into Wisconsin Site as Compounders Close In on Tirzepatide
December 6, 2024
 · 
2 min read
 · 
Tristan Manalac